StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-08 | $2.76 | $2.72 | -1.45% | 0.0M |
| 05-11 | $2.75 | $2.73 | -0.73% | 0.1M |
| 05-12 | $2.70 | $2.70 | +0.00% | 0.0M |
| 05-13 | $2.70 | $2.60 | -3.70% | 0.0M |
| 05-14 | $2.56 | $2.60 | +1.48% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for IMNN.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
Fundamentals not available for IMNN.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Annual 2022 2022-12-31 | Q3 2022 2022-09-30 | Q2 2022 2022-06-30 | Q1 2022 2022-03-31 |
|---|---|---|---|---|
Revenue | $500.00K | $375.00K | $250.00K | $125.00K |
Operating Income | $-24.92M | $-17.99M | $-11.82M | $-5.84M |
Net Income | $-35.90M | $-22.67M | $-16.52M | $-10.47M |
EPS (Diluted) | $-5.03 | $-3.42 | $-2.59 | $-1.82 |
Total Assets | $43.98M | $60.53M | $65.33M | $64.34M |
Total Liabilities | $14.65M | $19.18M | $18.29M | $18.08M |
Cash & Equivalents | $11.49M | $26.94M | $26.74M | $28.36M |
Free Cash Flow OCF − CapEx | $-23.36M | $-18.31M | $-13.62M | $-8.03M |
Shares Outstanding | 7.44M | 7.10M | 7.10M | 5.77M |